Login to Your Account

Clinic roundup

Friday, January 17, 2014
Biothera Inc., of Eagan, Minn., reported the results of its Phase II trial evaluating the effectiveness of Imprime PGG in combination with Erbitux (cetuximab), carboplatin and paclitaxel compared with the monoclonal antibody and chemotherapies alone in previously untreated patients with advanced non-small-cell lung cancer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription